WADA Eyes Weight Loss Drug Ban
The World Anti-Doping Agency is considering a ban on popular weight loss injection drugs ahead of the next Olympics. The decision will hinge on whether these medications are being abused for performance enhancement in bodybuilding and other strength sports, potentially risking athlete health or violating fair play principles.
- The class of drugs under scrutiny are GLP-1 receptor agonists, which include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro). These medications are primarily approved for treating type 2 diabetes and obesity. - While not currently on the prohibited list, WADA has included GLP-1 agonists in its Monitoring Program since 2024 to track for potential misuse by athletes. For a substance to be officially banned, it must meet at least two of three criteria: it enhances performance, poses a health risk, or violates the spirit of sport. - The primary concern is that athletes could use these drugs for rapid weight loss to improve their power-to-weight ratio, which is particularly advantageous in endurance sports. They work by suppressing appetite and slowing down the emptying of the stomach, making a person feel full for longer. - A potential decision on a ban could be made by the end of 2026 or in 2027, ahead of the Los Angeles 2028 Olympics. This timeline allows WADA to gather sufficient data on patterns of abuse in the sporting world. - Potential side effects and performance risks for athletes include the loss of lean muscle mass along with fat, which could negatively impact peak power and injury resilience. Other reported issues include nausea, reflux, and gastrointestinal discomfort during intense exercise. - If these drugs are banned, athletes with a legitimate medical need, such as those with Type 2 diabetes, could likely still access them through a Therapeutic Use Exemption (TUE). - This isn't the first time a substance has moved from the monitoring list to the prohibited list. The powerful painkiller Tramadol was monitored starting in 2012 and was subsequently banned from in-competition use in 2024 after WADA found evidence of significant use in sports. - Some medical experts express concern that using these drugs could lead to dangerously low blood sugar levels in highly-trained athletes, who are already very sensitive to insulin. There is also a lack of research on the effects of these medications on elite athletes, as the clinical trials were conducted on populations with obesity or diabetes.
